Chitosan and its derivatives: Potential excipients for peroral peptide delivery systems

International Journal of Pharmaceutics

Volumn 194, Issue 1, 2000, Pages 1-13

  Bernkop Schnürch, Andreas ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chitosan; Chitosan derivatives; Drug delivery systems; Peroral peptide application

Indexed keywords

BUSERELIN; CALCITONIN; CHITOSAN; CHITOSAN DERIVATIVE; EDETIC ACID; EXCIPIENT; INSULIN;

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; INTESTINE ABSORPTION; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CHITIN; CHITOSAN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HUMANS; PEPTIDES;

EID: 0033991816     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00365-8     Document Type: Review

References (52)

1. Aiedeh K., Gianasi E., Orienti I., Zecchi V. Chitosan microcapsules as controlled release systems for insulin. J. Microencapsul. 14:1997;567-576.
2. Arai K., Kinumaki T., Fujita T. Toxicity of chitosan. Bull. Tokai Reg. Fish Lab. 43:1968;89-94.
3. Artursson P., Lindmark T., Davis S.S., Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11:1994;1358-1361.
4. Aungst B.J., Saitoh H., Burcham D.L., Huang S.-M., Mousa S.A., Hussain M.A. Enhancement of the intestinal absorption of peptides and non- peptides. J. Contr. Release. 41:1996;19-31.
5. Bernkop-Schnürch A. Strategien zur peroralen Applikation von Peptid- und Proteinwirkstoffen. Sci. Pharm. 65:1997;61-82.
6. Bernkop-Schnürch A., Bratengeyer I., Valenta C. Development and in vitro evaluation of a drug delivery system protecting from trypsinic degradation. Int. J. Pharm. 157:1997;17-25.
7. Bernkop-Schnürch A., Paikl C., Valenta C. Novel bioadhesive chitosan-EDTA conjugate protects leucine enkephalin from degradation by aminopeptidase N. Pharm. Res. 14:1997;917-922.
8. Bernkop-Schnürch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control Release. 52:1998;1-16.
9. Bernkop-Schnürch A., Krajicek M.E. Mucoadhesive polymers for peroral peptide delivery: synthesis and evaluation of chitosan-EDTA conjugates. J. Control Release. 50:1998;215-223.
10. Bernkop-Schnürch A., Pasta M. Intestinal peptide and protein delivery: novel bioadhesive drug carrier matrix shielding from enzymatic attack. J. Pharm. Sci. 87:1998;430-434.
11. Bernkop-Schnürch, A., Paikl, C., 1998. Chitosan-conjugates with acidic chelate-complex forming agents. US-, European Patent WO 09831712A2.
12. Bernkop-Schnürch A., Scerbe-Saiko A. Synthesis and in vitro evaluation of chitosan-EDTA-protease-inhibitor conjugates which might be useful in oral delivery of peptides and proteins. Pharm. Res. 15:1998;263-269.
13. Bernkop-Schnürch A., Humenberger C., Valenta C. Basic studies on bioadhesive delivery systems for peptide and protein drugs. Int. J. Pharm. 165:1998;217-225.
14. Bernkop-Schnürch A., Krauland A., Valenta C. Development and in vitro evaluation of a drug delivery system based on chitosan-EDTA BBI conjugate. J. Drug Targ. 6:1998;207-214.
15. Bernkop-Schnürch A. Polymer-inhibitor conjugates: a promising strategy to overcome the enzymatic barrier to perorally administered (poly)peptide drugs. STP Pharma Sciences. 9:1999;78-87.
16. Bernkop-Schnürch A., Freudl J. Comparative in vitro study of different chitosan-complexing agent conjugates. Pharmazie. 54:1999;369-371.
17. Bernkop-Schnürch, A., Brandt, U.-M., Clausen, A., 1999. Synthesis and in vitro Evaluation of chitosan-cysteine conjugates. Sci. Pharm., in press.
18. Birk Y. The Bowman-Birk inhibitor. Int. J. Peptide Protein Res. 25:1985;113-131.
19. Borchard G., Lueßen H.L., Verhoef J.C., Lehr C.-M., de Boer A.G., Junginger H.E. The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption III: effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J. Control Release. 39:1996;131-138.
20. Dodane V., Khan A., Merwin J.R. Effect of chitosan on epithelial permeability and structure. Int. J. Pharm. 182:1999;21-32.
21. Felt O., Buri P., Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev. Ind. Pharm. 24:1998;979-993.
22. Fujii S., Yokoyama T., Ikegaya K., Sato F., Yokoo N. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J. Pharm. Pharmacol. 37:1985;545-549.
23. Ge Y.C., Morgan R.G.H. The effect of trypsin inhibitor on the pancreas and small intestine of mice. Br. J. Nutr. 70:1993;333-345.
24. Hassan E.E., Gallo J.M. A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength. Pharm. Res. 7:1990;491-495.
25. Ikesue K., Kopeckova P., Kopecek J. Degradation of proteins by guinea pig intestinal enzymes. Int. J. Pharm. 95:1993;171-179.
26. Illum L., Farraj N.F., Davis S.S. Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11:1994;1186-1189.
27. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15:1998;1326-1331.
28. Inoue K., Yamaguchi T., Shinbaru R., Hirakawa H., Yoshizuka K., Ohto K. Adsorption behaviors of some complexane types of chemically modified chitosan for metal ions. Domard A., Jeuniaux C., Muzzarelli R., Roberts G. Advances in Chitin Science. 1996;271-278 Jacques André Lyon.
29. Inoue K. Complexane types of chemically modified chitosan: Novel chelating absorbents for separating nickel and cobalt. Proc. Nickel-Cobalt 97 Int. Symp. 1:1997;211-219.
30. Khosla R., Davis S.S. The effect of polycarbophil on the gastric emptying of pellets. J. Pharm. Pharmacol. 39:1987;47-49.
31. Kotzé A.F., de Leeuw B.J., Lueßen H.L., de Boer A.G., Verhoef J.C., Junginger H.E. Chitosans for enhanced delivery of therapeutic peptides across intestinal epithelia: in vitro evaluation in Caco-2 cell monolayers. Int. J. Pharm. 159:1997;243-253.
32. Kotzé A.F., Lueßen H.L., de Boer A.G., Verhoef J.C., Junginger H.E. Chitosan for enhanced intestinal permeability: prospects for derivatives soluble in neutral and basic environments. Eur. J. Pharm. Sci. 7:1998;145-151.
33. Kotzé A.F., Thanou M.M., Lueßen H.L., de Boer A.G., Verhoef J.C., Junginger H.E. Enhancement of paracellular drug transport with highly quarternized N-trimethyl chitosan chloride in natural environments: in vitro evaluation in intestinal epithelial cells (Caco-2). J. Pharm. Sci. 88:1999;253-257.
34. Langguth P., Merkle H.P., Amidon G.L. Oral absorption of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid. Pharm. Res. 11:1994;528-535.
35. Lee V.H.L. Oral route of peptide and protein drug delivery. Gardner M.L.G., Steffens K.-J. Absorption of Orally Administered Enzymes. 1995;39-46 Springer Verlag, Berlin.
36. Lehr C.-M. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug. 11:1994;119-160.
37. Lehr C.-M., Bouwstra J.A., Schacht E.H., Junginger H.E. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 78:1992;43-48.
38. Lindahl A., Ungell A.-L., Knutson L., Lennernäs H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm. Res. 14:1997;497-502.
39. Lueßen H.L., Rentel C.-O., Kotzé A.F., Lehr C.-M., de Boer A.G., Verhoef J.C. et al. Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J. Control Release. 45:1997;15-23.
40. Lueßen H.L., de Leeuw B.J., Langemeyer M.W., de Boer A.G., Verhoef J.C., Junginger H.E. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm. Res. 13:1996;1668-1672.
41. Melmed R.N., El-Aaser A.A., Holt S.J. Hypertrophy and hyperplasia of the neonatal rat exocrine pancreas induced by orally administered soy bean trypsin inhibitor. Biochim. Biophys. Acta. 421:1976;280-288.
42. Morishita I., Morishita M., Takayama K., Machida Y., Nagai T. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int. J. Pharm. 78:1992;9-16.
43. Schipper N.G.M., Varum K.M., Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: influence of molecular weight and degree of acetlyation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm. Res. 13:1996;1686-1691.
44. Schipper N.G.M., Olsson S., Hoogstraate J.A., de Boer A.G., Varum K.M., Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm. Res. 14:1997;923-929.
45. Schipper N.G.M., Varum K.M., Stenberg P., Ocklind G., Lennernäs H., Artursson P. Chitosans as absorption enhancers of poorly absorbable drugs 3: influence of mucus on absorption enhancement. Eur. J. Pharm. Sci. 8:1999;335-343.
46. Takeuchi H., Yamamoto H., Toshiyuki N., Tomoaki H., Kawashima Y. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm. Res. 13:1996;896-901.
47. Takeuchi H., Matsui Y., Yamamoto H., Kawashima Y. Mucoadhesive liposomes coated with chitosan or carbopol for oral administration of peptide drugs. Proc. Int. Symp. Control. Rel. Bioact. Mater. 26:1999;6372.
48. Tikhonov V.E., Radigina L.A., Yamskov Y.A. Metal-chelating chitin derivatives via reaction of chitosan with nitrilotriacetic acid. Carbohydr. Res. 290:1996;33-41.
49. Valenta, C., Christen, B., Bernkop-Schnürch, A., 1998. Chitosan-EDTA conjugate: a novel polymer for topical used gels. J. Pharm. Pharmacol. 50, 445-452.
50. Woodley J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug. 11:1994;61-95.
51. Yamamoto A., Taniguchi T., Rikyuu K., Tsuji T., Fujita T., Murakami M. et al. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11:1994;1496-1500.
52. Zhou X.H. Overcoming enzymatic and absorption barriers to nonparenterally administered protein and peptide drugs. J. Control Release. 29:1994;239-252.